Novak Alfred J
Known title: DirectorCIK: 0001388862
Associated companies
Transaction History
| KTTA | ▲ Buy | Grant | 2,750 | $15K | 6/13/2024 | View on chart |
| KTTA | ▲ Buy | Grant | 750 | $4K | 6/12/2024 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 1,346 | $0 | 6/15/2022 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 97 | $6K | 6/15/2022 | View on chart |
| LIVN | ▼ Sell | Open Market | 2,337 | $208K | 11/11/2021 | View on chart |
| LIVN | ▼ Sell | Open Market | 644 | $58K | 11/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
LivaNova Shares Rise on Barclays Overweight Rating
Barclays has begun coverage of LivaNova, giving it an overweight rating and a $105 price target. The stock is currently trading near the upper end of its 52‑week range and has been on a 60% three‑year run, which some analysts see as undervalued. Technical indicators show an RSI of 45 and a support level at $78.13, with a support reject signal that may signal a short‑term consolidation.
LivaNova Shares Rise on Barclays Overweight Rating. Barclays has begun coverage of LivaNova, giving it an overweight rating and a $105 price target. The stock is currently trading near the upper end of its 52‑week range and has been on a 60% three‑year run, which some analysts see as undervalued. Technical indicators show an RSI of 45 and a support level at $78.13, with a support reject signal that may signal a short‑term consolidation.